Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Dorzolamide (compound)

Name: dorzolamide
PubChem Compound ID: 10520464
Molecular formula: C10H16N2O4S3
Molecular weight: 330.467 g/mol
Name: dorzolamide
Name (isomeric): DB00869
Drug Type: small molecule
Brand: Trusopt
Brand name mixture: Cosopt(Dorzolamide (Dorzolamide Hydrochloride) + Timolol (Timolol Maleate))
Category: Carbonic Anhydrase Inhibitors, Antihypertensive Agents
CAS number: 120279-96-1
Indication: For the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Also used prophylatically for the inhibition of perioperative IOP increase (before neodynium yttrium aluminum garnet laser posterior capsulotomy).
Pharmacology: Dorzolamide is topical CA inhibitor that is indicated for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers. Dorzolamide reduces IOP by approximately 17-23% in patients with elevater IOP.
Mechanism of Action:
Dorzolamide is a sulfonamide and a highly specific carbonic anhydrase II (CA-II) inhibitor, which is the main CA isoenzyme involved in aqueous humor secretion. Inhibition of CA-II in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and flu...
show more »
Protein binding: ~33%
Route of elimination: Dorzolamide is primarily excreted unchanged in the urine; the metabolite also is excreted in urine.
Half Life: 4 months
Toxicity: Dizziness, headache, shortness of breath, slow heartbeat, severe asthma, cardiac arrest
Affected organisms: Humans and other mammals
Drug interaction:
BrinzolamideAs both brinzolamide and dorzolamide are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible.